Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lymphomyosot is a homeopathic complex preparation developed by Biologische Heilmittel Heel GmbH and distributed in the United States by MediNatura. It is composed of a specific mixture of botanical, mineral, and animal-derived ingredients, including *Myosotis arvensis*, *Scrophularia nodosa*, and *Aranea diadema*, prepared in homeopathic dilutions. The product is primarily indicated for the treatment of lymphatic system disorders, such as lymphoedema, and for the reduction of tissue edema and swelling associated with trauma or inflammation. While it has been marketed for over 70 years and used in clinical settings for conditions like post-traumatic edema following ankle fractures, it has recently faced regulatory scrutiny from the FDA as an unapproved new drug, leading to import restrictions and legal challenges regarding its status in the U.S. market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lymphomyosot.